Gout

New England Journal of Medicine

Volumn 349, Issue 17, 2003, Pages 1647-1655

  Terkeltaub, Robert A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CELECOXIB; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ERYTHROMYCIN; ETORICOXIB; INDOMETACIN; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE; PREDNISONE; PROBENECID; ROFECOXIB; SIMVASTATIN; SULFINPYRAZONE; SULINDAC; TRIAMCINOLONE ACETONIDE; URIC ACID; ANTIGOUT AGENT;

ADULT; ARTHROCENTESIS; ARTICLE; ASTHMA; BLEEDING; BONE MARROW SUPPRESSION; CASE REPORT; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEHYDRATION; DIARRHEA; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; MALE; MYOPATHY; NAUSEA; NEUTROPENIA; OBESITY; PEPTIC ULCER; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RASH; URIC ACID BLOOD LEVEL; UROLITHIASIS; VOMITING; BLOOD; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PRACTICE GUIDELINE; REVIEW;

ADRENAL CORTEX HORMONES; ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, GOUTY; COLCHICINE; DIAGNOSIS, DIFFERENTIAL; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; URIC ACID;

EID: 0142123411     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp030733     Document Type: Article

References (53)

1. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40:37-42.
2. Wu X, Wakamiya M, Vaishnav S, et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 1994;91:742-6.
3. Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002;29:1942-9.
4. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002;14:281-6.
5. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
6. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000;27:1045-50.
7. Waller PC, Ramsay LE. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens 1989;3:457-61.
8. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002;168:1307-14.
9. O'Duffy JD, Hunder GG, Kelly PJ. Decreasing prevalence of tophaceous gout. Mayo Clin Proc 1975;50:227-8.
10. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol 2001;13:240-4.
11. Puig JG, Michan AD, Jimenez ML, et al. Female gout: clinical spectrum and uric acid metabolism. Arch Intern Med 1991;151:726-32.
12. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000;11:974-9.
13. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weightloss associated with moderate calorie/ carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000;59:539-43.
14. Simmonds HA, Duley JA, Fairbanks LD, McBride MB. When to investigate for purine and pyrimidine disorders: introduction and review of clinical and laboratory indications. J Inherit Metab Dis 1997;20:214-26.
15. Terkeltaub RA. Pathogenesis and treatment of crystal-induced inflammation. In: Koopman WJ, ed. Arthritis and allied conditions: a textbook of rheumatology. 14th ed. Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:2329-47.
16. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.
17. Schworer H, Ramadori G. Treatment of acute gouty arthritis with the 5-hydroxytryptamine antagonist ondansetron. Clin Investig 1994;72:811-3.
18. Schlesinger N, Detry MA, Holland BK, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002;29:331-4.
19. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5.
20. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994;21:696-9.
21. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-7.
22. Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002;46:2765-75.
23. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2001;35:365-8.
24. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17:301-4.
25. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002;22:385-7.
26. Harris R, Marx G, Gillett M, Kark A, Arunanthy S. Colchicine-induced bone marrow suppression: treatment with granulocyte colony-stimulating factor. J Emerg Med 2000;18:435-40.
27. Baud FJ, Sabouraud A, Vicaut E, et al. Treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med 1995;332:642-5.
28. Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol 1995;22:1618-9.
29. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-9.
30. Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E. Acute colchicine intoxication - possible role of erythromycin administration. J Rheumatol 1992;19:494-6.
31. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002;25:266-8.
32. Ducloux D, Schuller V, Bresson-Vautrin C, Chalopin JM. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant 1997;12:2389-92.
33. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989;16:1246-8.
34. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-8.
35. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal under-excretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002;47:610-3.
36. Becker MA. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am 1988;14:377-94.
37. Yamamoto T, Moriwaki Y, Takahashi S, et al. A simple method of selecting gout patients for treatment with uricosuric agents, using spot urine and blood samples. J Rheumatol 2002;29:1937-41.
38. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
39. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
40. Harris M, Bryant LR, Danaher P, Alloway J. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol 2000;27:2873-6.
41. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-8.
42. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
43. Stamp L, Gow P, Sharples K, Raill B. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000;30:567-72.
44. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
45. Walter-Sack I, de Vries JX, Kutschker C, Ittensohn A, Voss A. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur J Clin Pharmacol 1995;49:215-20.
46. Kamper AL, Nielsen AH. Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001;72:671-4.
47. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56:1879-85. [Erratum, Kidney Int 2000;57:370.]
48. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56:1879-85. [Erratum, Kidney Int 2000;57:370.]
49. Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001;16:1034-7.
50. Sica DA, Schoolwerth AC. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-82.
51. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997.
52. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33:225-34.
53. Romeijnders ACM, Gorter KJ. Samenvatting van de standaard 'Jicht' van het Nederlands Huisartsen Genootschap. Ned Tijdschr Geneeskd 2002;146:309-13.